methylphenidate sandoz forðatafla 18 mg
sandoz a/s* - methylphenidatum hýdróklóríð - forðatafla - 18 mg
methylphenidate sandoz forðatafla 36 mg
sandoz a/s* - methylphenidatum hýdróklóríð - forðatafla - 36 mg
methylphenidate teva hart hylki með breyttan losunarhraða 10 mg
teva b.v.* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 10 mg
methylphenidate teva hart hylki með breyttan losunarhraða 20 mg
teva b.v.* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 20 mg
methylphenidate teva hart hylki með breyttan losunarhraða 30 mg
teva b.v.* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 30 mg
methylphenidate teva hart hylki með breyttan losunarhraða 60 mg
teva b.v.* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 60 mg
methylphenidate medical valley forðatafla 54 mg
medical valley invest ab - methylphenidatum hýdróklóríð - forðatafla - 54 mg
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dímetýl fúmarat - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate mylan
mylan ireland limited - dímetýl fúmarat - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate polpharma
zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dímetýl fúmarat - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.